Cardiopirin

Aspirin

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardiopirin

This section provides a factual overview of the identity, composition, and general purpose of Cardiopirin, adhering strictly to its definitional scope.

Property	Description
Active ingredient	Acetylsalicylic acid (ASA)
Form	Oral tablet (often enteric-coated)
Pharmacological class	Antiplatelet Agent and Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use	Cardiovascular prophylaxis (antithrombotic effect)
Origin	Synthetic

What Type of Medication is Cardiopirin? (Identity and Classification)

Cardiopirin is a medicinal product defined by its active chemical ingredient, Acetylsalicylic acid (ASA), which is the non-proprietary name for Aspirin. Chemically, it falls under the broad class of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), but its primary function at the concentrations used leads to its specific classification as an Antiplatelet Agent. This specialized status is clinically recognized for its focused action on blood components. Cardiopirin is a synthetic, low-dose formulation intended specifically for its long-term antithrombotic properties, distinguishing its therapeutic position from higher-dose NSAIDs used for acute pain relief.

Composition, Formulation, and Purpose (Form and Structure)

The product is a single active ingredient product administered via the Oral route, most commonly supplied as an Enteric-coated tablet. This enteric-coated tablet formulation is a distinct feature intended to resist the acidic environment of the stomach, delaying the release of the ASA until the tablet reaches the small intestine. This delayed release mechanism is important for medications requiring long-term, sustained administration. The design facilitates consistent administration, which is crucial for its role in long-term support.

The medication's general purpose is to leverage its unique ability to inhibit platelet aggregation, thereby reducing the capacity of blood components to stick together and form unwanted clots in the arteries. This mechanism helps reduce the stickiness of blood platelets to support the overall cardiovascular system.

Regulatory References

NIH: Antithrombotic properties of aspirin

What side effects are possible with Cardiopirin?

Possible Side Effects and Safety Information

The safety profile for Cardiopirin (low-dose Acetylsalicylic acid / ASA) is officially documented by government regulatory agencies and is primarily defined by the risk of bleeding and gastrointestinal adverse events.

Officially Documented Adverse Reactions

Adverse reactions are classified by frequency and System-Organ Class (SOC) in regulatory documents (e.g., FDA/EMA labeling).

Frequency Classification	Examples of Officially Listed Side Effects
Common (e.g., ge1/100)	Dyspepsia, increased general risk of bleeding
Uncommon (e.g., ge1/1,000)	Hypersensitivity reactions (e.g., urticaria, rhinitis), minor GI haemorrhage
Rare (e.g., ge1/10,000)	Serious gastrointestinal haemorrhage, ulceration, or perforation; thrombocytopenia

Major System-Organ Classes involved include Gastrointestinal Disorders, Blood and Lymphatic System Disorders, Immune System Disorders, and Nervous System Disorders.

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions explicitly documented in official labeling include life-threatening events such as Gastrointestinal haemorrhage, ulceration, or perforation, and Haemorrhagic stroke. Severe hypersensitivity reactions, including anaphylaxis, are also listed.

Population-Specific Safety Constraints are a critical component of the official safety profile:

Paediatrics/Adolescents: The use of ASA is officially restricted in children and teenagers with viral infections due to the documented, rare risk of Reye's syndrome.
Older Adults: Have an officially documented increased risk of serious gastrointestinal bleeding.
Organ Impairment: Cardiopirin is officially constrained or contraindicated in patients with severe hepatic or renal insufficiency.

This official safety documentation is structured to communicate the risk of haemorrhage as the primary concern, while also defining the mandatory restrictions for vulnerable populations and those with pre-existing conditions.

Overdose and Emergency Response

Overdose of Cardiopirin (acetylsalicylic acid) is a potentially severe condition classified into moderate and severe intoxication by regulatory authorities. Initial symptoms of moderate intoxication, known as Salicylism, are documented to include tinnitus, hearing impairment, nausea, vomiting, and hyperventilation.

The profile for severe overdose involves critical, life-threatening manifestations affecting multiple physiological systems. These officially documented outcomes include severe metabolic acidosis, profound hypoglycemia, cerebral edema, seizures, progression to coma, acute renal failure, and cardiovascular collapse.

Overdose Classification	Key Manifestations Listed in Regulatory Documents
Moderate Intoxication	Tinnitus, nausea, hyperventilation, hearing impairment.
Severe Intoxication	Seizures, metabolic acidosis, pulmonary oedema, coma.

When to Seek Urgent Medical Help

Regulatory guidance mandates that any suspected Cardiopirin overdose requires the patient to seek immediate medical attention and necessitates hospital admission. This urgent action is required due to the risk of rapid clinical deterioration and the fact that no specific antidote is known. Management relies entirely on supportive measures, correction of metabolic disturbances, and enhanced elimination procedures, such as urinary alkalinization or haemodialysis for the most severe cases. Special care is noted in official labeling for vulnerable populations, including young children and the elderly, who are at increased risk of severe toxicity.

Therapeutic Uses of Cardiopirin

Cardiopirin: Main Uses and Benefits

Cardiopirin is a medication that contains acetylsalicylic acid, commonly used in a low dose for its antiplatelet effect. The primary role of this agent is to assist in inhibiting platelet aggregation, a critical mechanism in the formation of blood clots.

The main therapeutic application of Cardiopirin focuses on cardiovascular and cerebrovascular health, typically in a preventative role. It is used for the secondary prevention of serious vascular events in patients who have previously experienced a myocardial infarction (heart attack) or ischemic stroke. The medicine also has an established role in reducing the risk of a first myocardial infarction in specific patients determined to be at a high cardiovascular risk.

Key uses include:

Reducing the risk of recurrent myocardial infarction and stroke in patients with established disease.
Preventing blood clots in patients with stable or unstable angina (a type of chest discomfort).
Prophylaxis after certain vascular procedures, such as coronary bypass surgery, to prevent vessels from clogging.

Before initiating an aspirin regimen, it is crucial to consult a healthcare professional to assess the individual risk-benefit profile, particularly regarding the risk of bleeding. Comprehensive guidance exists regarding appropriate indications for using aspirin to reduce the risk of a first or subsequent heart attack and stroke.

Quick Facts

Therapeutic Role: Inhibits platelet aggregation.
Primary Treatment Area: Secondary prevention of myocardial infarction and ischemic stroke.
Additional Use: Prevention of blood clots in patients with angina and following certain vascular procedures.

Eligibility and Restrictions for Use

Eligibility for Cardiopirin (Low-Dose Acetylsalicylic Acid)

Official regulatory information defines who may or must not use Cardiopirin based on specific health status, age, and physiological states. Use is established primarily for adults for cardiovascular prophylaxis.

Contraindicated Populations (Must Not Use)	Conditional or Restricted Use
Allergy/Hypersensitivity: History of severe allergic reaction to ASA or other NSAIDs.	Organ Impairment: Moderate hepatic or renal impairment requires careful medical monitoring.
Active Bleeding: Active peptic ulcer disease or other active pathological bleeding.	GI History: History of stomach ulcers or gastrointestinal bleeding requires careful medical supervision.
Severe Organ Failure: Severe hepatic impairment, severe renal impairment, or severe uncontrolled heart failure.	Older Adults: At an officially documented greater risk for serious gastrointestinal events.
Pregnancy: Absolutely prohibited in the third trimester (starting at 30 weeks gestation).	Early Pregnancy: Restricted in the first and second trimesters; use must be medically indicated.
Pediatrics: Children and adolescents (typically under 16 years) with viral symptoms due to the risk of Reye’s syndrome.	Lactation: Generally not recommended; consult regulatory advice.

Eligibility is strictly tied to documented criteria, with use for the antiplatelet indication being not established in the pediatric population.

What should I know about interactions with other medicines?

The official regulatory profile for Cardiopirin (Acetylsalicylic acid) focuses on interactions that increase bleeding risk, interfere with its antiplatelet efficacy, or modify drug exposure.

Interaction Scope

Interacting Product Categories:

Oral Anticoagulants, Other Antiplatelet Agents, and Selective Serotonin Reuptake Inhibitors (SSRIs): Co-administration with these agents results in an additive increased risk of haemorrhage due to pharmacodynamic effects.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Use of NSAIDs at analgesic/anti-inflammatory doses is contraindicated due to the severe, additive risk of gastrointestinal bleeding and ulceration.
Methotrexate and Digoxin: Co-administration involves a reduced renal clearance mechanism, which can elevate and/or prolong serum levels of these two specific medicines.

Official Restrictions:

Ibuprofen (Immediate-release formulation): Ibuprofen may cause pharmacodynamic interference that reduces the antiplatelet efficacy of ASA. To avoid this, regulators specify a timing separation requirement: the ibuprofen dose must be administered at least 8 hours before or at least 30 minutes after the immediate-release ASA dose.
Alcohol and Corticosteroids: The risk of serious gastrointestinal bleeding is officially documented to be increased with co-administration of chronic/heavy alcohol use and also with corticosteroids.

Population-Specific Notes:

Caution is noted for co-administration with ACE Inhibitors/ARBs in elderly, volume-depleted, or renally-impaired patients due to the potential risk of deterioration of renal function.

Mechanism of Action

Irreversible Blockade of Platelet COX-1

Cardiopirin's primary mechanism involves the irreversible inhibition of the Cyclooxygenase-1 (COX-1) enzyme within circulating platelets. This action is achieved through covalent acetylation, which permanently deactivates the enzyme, thus interfering with a specific signaling component of the hemostatic system. This molecular blockade alters the platelet's function for the duration of its lifespan.

Modulating the Clotting Signal Cascade

The irreversible blockade of COX-1 arrests a crucial step in the Arachidonic Acid Pathway, specifically preventing the synthesis of Thromboxane A2 (TXA2). TXA2 is a chemical mediator that signals platelets to activate and aggregate. By eliminating this signal, the mechanism reduces the capacity for platelet aggregation.

Sustained Reduction in Platelet Aggregation

The resulting physiological change is a sustained systemic reduction in platelet aggregation capacity. This outcome is directly linked to the suppressed ability of platelets to clump together. The change in aggregation capacity influences the drug’s pharmacological profile without impacting the liquid coagulation cascade.

Dosage and Administration Information

Cardiopirin is administered exclusively by the oral route, with the treatment protocol focused on sustaining a low, fixed daily dose. The standard maintenance dose for long-term use typically ranges from 75 mg to 100 mg once daily, though specified maintenance ranges may extend up to 325 mg for certain cardiovascular regimens.

For chronic prophylaxis, the medication is intended for long-term or indefinite duration. The tablet is taken once daily at approximately the same time each day to ensure sustained antiplatelet action. It is generally instructed to be taken with or immediately after food using a full glass of water, which is a procedural condition of administration.

A critical procedural constraint involves the handling of the dosage form. The commonly supplied enteric-coated tablets must be swallowed whole and must not be split, crushed, or chewed, as this defeats the coating designed to regulate release. If a daily dose is missed, the protocol for a missed dose involves skipping the missed dose if it is near the time for the next scheduled dose, and never taking a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cardiopirin

This section provides an overview of the research studies that have evaluated Cardiopirin (low-dose acetylsalicylic acid), focusing on the types of evidence reported in scientific sources.

Evidence for use in Established Heart and Blood Vessel Disease (Secondary Prevention)

Research has extensively examined the use of Cardiopirin in adults who already have established Atherosclerotic Cardiovascular Disease (ASCVD). These studies primarily consist of large-scale Randomized Controlled Trials (RCTs) that monitored the occurrence of subsequent vascular events, such as non-fatal heart attack or non-fatal ischemic stroke. Findings from available trials consistently report lower measurements of recurrent non-fatal events in the Cardiopirin groups compared to control groups in established disease populations. Some older foundational trials used in research exploring a range of different doses of acetylsalicylic acid.

Evidence for use in Preventing a First Event (Primary Prevention)

The research for primary prevention involves several long-term Randomized Controlled Trials (RCTs) research examined whether initiating Cardiopirin was associated with differences in the first occurrence of vascular events in high-risk adults who had no history of prior heart attack or stroke. Findings from these trials describe patterns observed showing fewer first non-fatal heart attack events. However, these same studies reported that the absolute number of events prevented was modest. Scientific certainty remains low regarding the overall clinical value in this area, as data show patterns related to modest differences in outcomes, and findings were mixed regarding all-cause mortality.

Evidence Gaps and Areas of Scientific Uncertainty

Research has explored how Cardiopirin was associated with outcomes in specific cohorts, including older adults and patients with Diabetes Mellitus. However, data for certain groups remain insufficient to draw broad conclusions. Long-term effects are not fully established, and the optimal long-term duration for the regimen’s study following initial research phases is an area of ongoing research. Ultimately, findings describe group patterns, not personal outcomes, meaning that the research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Cardiopirin (FAQ)

Q: How quickly does Cardiopirin start to work for its main purpose?

Cardiopirin's primary mechanism involves the irreversible inhibition of the COX-1 enzyme in platelets. Official product information indicates that because this process is permanent for each affected platelet, the effect is generally described as lasting for the lifespan of the platelet, which is cited to be about 7 to 10 days.

Q: Can Cardiopirin cause stomach upset, and is that a common side effect?

Stomach upset or indigestion (dyspepsia) is officially documented as a common adverse reaction to Cardiopirin. According to regulatory safety data, a common reaction means it may occur in one or more out of every 100 people taking the medicine.

Q: Why do some people need to take Cardiopirin even if they don't have heart problems?

Official guidance notes the consideration of this medicine for certain adults who are at a higher risk of developing atherosclerotic cardiovascular disease but who are not deemed to be at an increased risk of bleeding. This use is known as primary prevention.

Q: Can people with kidney issues use Cardiopirin?

Official information states that the use of Cardiopirin is not recommended in patients with severe renal (kidney) impairment. Official labels indicate that consultation with a doctor is advised if kidney disease, high blood pressure, or the use of certain other medications are present.

Q: Is Cardiopirin used for stroke prevention?

According to official indications, Cardiopirin is used to reduce the risk of stroke. This use is noted for patients who have previously had an ischemic stroke or a transient ischemic attack (a mini-stroke), as well as in the prevention of a first stroke in high-risk patients.

Q: Is it okay to take Cardiopirin before minor dental procedures?

Regulatory sources document that this medication prolongs bleeding time because it inhibits platelet function. For this reason, stopping the medicine before minor or elective procedures is a common consideration, but healthcare professionals typically make this decision based on an assessment of individual patient factors.

Q: How long after taking Cardiopirin should I wait before having a surgery?

Due to the irreversible nature of the antiplatelet effect, regulatory-cited sources note the effect can last for approximately 7 to 10 days. This is the rationale medical providers use to determine the appropriate time based on an individual patient assessment before surgery.

Q: Does Cardiopirin have an impact on blood pressure?

While not a primary indication, official labels indicate that consultation with a doctor is advised in cases of high blood pressure or existing heart disease before using Cardiopirin.

Q: Is there a risk of developing an allergy to Cardiopirin after using it for a while?

Hypersensitivity reactions, which are allergic reactions such as hives or anaphylaxis, are listed as known adverse reactions in official safety documents. It is documented that the medicine is contraindicated (must not be used) if a patient has a known history of severe allergy to it.

Q: What kind of research has been done on the long-term safety of Cardiopirin?

Long-term safety research reviewed by regulatory bodies focuses on monitoring specific risks. These include gastrointestinal adverse reactions like ulceration and bleeding, as well as the potential for abnormal laboratory test results, such as elevated liver enzymes, during sustained use.

Q: Can Cardiopirin affect the results of certain lab tests?

Official information indicates that Cardiopirin can influence the results of some laboratory tests. It has been associated with changes in readings for liver enzymes, blood urea nitrogen, and serum creatinine, and it can prolong bleeding time.

Q: What happens in the body when Cardiopirin is stopped suddenly?

Official guidelines underscore that Cardiopirin is intended for long-term use in chronic conditions. The discontinuation of antiplatelet therapy may be associated with an increased risk of recurrent cardiovascular events in patients using it for secondary prevention.

Q: Can Cardiopirin be used by people who have diabetes?

Official regulatory labels advise that patients with diabetes should consult a healthcare professional before use. Research reviewed by regulatory bodies on the effects in diabetic patients has indicated that the findings showed modest differences in outcomes.

Q: How does Cardiopirin work to help circulation?

Cardiopirin works by targeting specific components in the blood. Its mechanism reduces the capacity for blood components called platelets to clump together and form unwanted clots in the arteries, which helps support the system of blood flow, or circulation.

Q: Does Cardiopirin interact with any common vitamins or supplements?

Regulatory-related resources note that some high-dose supplements, such as Vitamin E, may increase the antiplatelet effects of Cardiopirin. Additionally, the medicine may influence the status of Vitamin C in the body.

Q: What is the longest amount of time research supports taking Cardiopirin?

For its use in secondary prevention, regulatory-cited guidelines state that the maintenance dose is often taken indefinitely. Research has established the safety and effectiveness of the regimen over many years, though its optimal long-term study duration is ongoing.

Q: Can Cardiopirin cause heartburn, and if so, how is that managed?

Heartburn is a symptom related to the officially listed side effect of dyspepsia (indigestion). Some official labels advise patients who have a history of stomach issues, including heartburn, to consult a doctor before using the medication due to the potential risk.

Q: Why is this medication not for use in children?

The medication is officially restricted in children and adolescents, particularly those with viral symptoms. This is due to the documented, rare risk of a serious condition called Reye's syndrome.

Q: What is the usual duration of the effect after taking one dose of Cardiopirin?

The antiplatelet effects are described as being irreversible, meaning they last for the entire life of the affected platelets. Therefore, the antiplatelet effect is sustained for approximately 7 to 10 days after a single dose.

Q: Can Cardiopirin be taken by someone with mild liver impairment?

The use of Cardiopirin is not recommended in patients with severe liver disease. Official regulatory documents indicate that consultation with a doctor is advised for patients with liver disease.

Q: Why must I inform other doctors that I am taking Cardiopirin?

Official warnings note that informing all healthcare providers, including dentists, is necessary. This is because the medicine prolongs bleeding time and has known interactions with many other medications, such as NSAIDs and anticoagulants.

Q: Does Cardiopirin interact with any herbal remedies like ginkgo biloba?

Regulatory-related drug interaction resources indicate that some herbal remedies, such as Ginkgo Biloba, may increase the risk of bleeding. Taking this remedy with an antiplatelet agent like Cardiopirin may further potentiate (increase) that risk.

Q: Is Cardiopirin associated with any changes in mood or sleep?

Official regulatory documents list 'Nervous System Disorders' as a category of adverse reactions. While specific changes to mood or sleep are not detailed in the common side effect listings, general effects like headache and dizziness are noted.

Q: What is the purpose of the lower strength Cardiopirin tablets?

The lower strengths, which typically range from 75 mg to 100 mg, are officially indicated for cardiovascular prophylaxis. This means their purpose is specifically the reduction of blood clots and the prevention of heart attacks and strokes.

Q: How is Cardiopirin different from other drugs that treat similar conditions?

Regulatory-based comparison charts distinguish Cardiopirin from other antiplatelet agents by its specific mechanism of action. It works by causing the irreversible inhibition of the COX-1 enzyme, which is a unique characteristic among medicines used to reduce the risk of clotting.

Q: Is it necessary to wait a certain amount of time between taking Cardiopirin and other medicines?

Official regulatory warnings specify a timing separation requirement for certain drugs. For example, immediate-release Ibuprofen should be taken at least 8 hours before or 30 minutes after Cardiopirin to avoid potential interference with its intended action.

Q: What percentage of people experience the most common side effects of Cardiopirin?

Official regulatory documents classify common side effects as occurring in one or more out of every 100 people (geq1/100). These documents typically use this frequency category rather than providing a more specific numerical percentage.

Q: Is Cardiopirin considered a generic or a brand-name drug?

Cardiopirin is considered a brand name for the active chemical ingredient, Acetylsalicylic acid (ASA). Acetylsalicylic acid is the generic, non-proprietary name for aspirin.

How should Cardiopirin be stored and disposed of?

Storage Conditions and Environmental Protection

Cardiopirin (acetylsalicylic acid) must be stored at controlled room temperature, typically defined as below 25 C and protected from freezing

The medication must be kept in its original container and the container must be tightly closed to protect the tablets from moisture and light. Exposure to moisture can cause the tablets to degrade, often indicated by a strong vinegar odor, at which point the medicine should be discarded regardless of the expiration date.

Disposal and Child Safety

It is a mandatory requirement to store the medicine out of the sight and reach of children.

Unused or expired Cardiopirin must be disposed of according to local regulations. Consumers are generally advised to use drug take-back programs and should not flush the tablets down the toilet unless the labeling specifically instructs them to do so.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.